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Analysis of risk factors for vitamin B12  
deficiency in patients with type 2  
diabetes mellitus and its relation  
to the use of metformin
ABSTRACT
Background. The use of metformin has been associated 
with vitamin B12 deficiency in patients with type 2 
diabetes mellitus. 
Objective. The present study evaluates the relationship 
between vitamin B12 deficiency and its risk factors. 
Moreover, it investigates the relationship between 
established deficiency and clinically detectable periph-
eral neuropathy.
Material and methods. A cross-sectional study invol-
ving patients with type 2 diabetes mellitus who were 
assisted at a public health care service, which is a refe-
rence center in Diabetes. Peripheral neuropathy was 
detected by Neuropathy Symptom Score, Vibration 
Sensitivity Test, Achilles Reflex and Monofilament Test. 
Vitamin B12 levels were determined by means of two 
laboratory measurements.
Results. The study included 316 subjects, from which 
91% were metformin users. Vitamin B12 deficiency 
was observed in 14% of participants in the study. All 
patients with vitamin B12 deficiency used metformin, 
with an odds ratio of 2.6 for those using doses higher 
than 1000 mg/day (95% confidence interval: 1.3–5.3, 
p = 0.009). Vitamin B12 deficiency was also statisti-
cally related to the use of angiotensin-converting 
enzyme inhibitors (p = 0.02). Peripheral neuropathy 
was observed in 41% of patients and was not related 
to vitamin B12 deficiency. The prevalence of peripheral 
neuropathy was lower among metformin users (39% 
vs. 60%; p = 0.04).
Conclusions. This study demonstrated a dose-depend-
ent association between metformin use and vitamin 
B12 deficiency, in addition to an association with the 
use of angiotensin-converting enzyme inhibitors. In 
contrast, Vitamin B12 deficiency was not related to 
clinically detected neuropathy. (Clin Diabetol 2018; 
7, 6: 247–252)
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Introduction
Metformin is the most widely used oral anti hyper-
glycemic agent [1]. Most current clinical recommenda-
tions suggest that, in the absence of contraindications, 
metformin should be the first-line medication for the 
treatment of type 2 diabetes mellitus (T2DM) [2, 3]. 
Most of the side effects of metformin are mild, transient 
or clinically difficult to detect, such as B12 deficiency 
signs [4–9]. 
The association of vitamin B12 deficiency with the 
development of megaloblastic anemia has been well 
established [10–12]. Anemia and macrocytosis can be 
found, respectively, in 29% and 36% of the population 
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with cobalamin deficiency [10]. Another consequence 
of vitamin B12 deficiency is peripheral neuropathy, 
whose initial manifestations, such as paresthesia and 
loss of sensitivity to vibration, can be easily confused 
with the initial presentation of diabetic neuropathy 
[11–13]. About 50% of patients with T2DM will develop 
some degree of diabetic neuropathy throughout their 
lifetime [14–16]. The clinical suspicion of vitamin B12 
deficiency, based on neurological findings, is impaired 
in this group of patients, leading to a possible under-
diagnosis of this important vitamin deficiency. This 
situation may result in permanent neurological dam-
age if it is not adequately identified and treated [17].
Due to the large number of individuals using 
metformin, the implementation of a universal screen-
ing routine requires higher costs for the public health 
system. Therefore, the identification of risk factors 
associated with the development of such deficiency is 
a way of facilitating the screening of susceptible pa-
tients. This is one way to propose a more economical 
screening system. 
The aim of this study was to correlate vitamin B12 
deficiency with the use of metformin and to identify 
other risk factors, such as other medications used by 
patients with T2DM. A further objective was to inves-
tigate the association between peripheral neuropathy 
and the detection of vitamin B12 deficiency in this 
group of patients.
Materials and methods
A cross-sectional study that evaluated patients with 
T2DM enrolled into the public diabetes health care pro-
gram in the region of Cariacica, Espírito Santo, Brazil.
Ethical aspects
The study protocol was approved by the local 
research ethics committee and all study participants 
provided a written informed consent. 
Selection of the patients
Patients diagnosed with T2DM, based on the crite-
ria of the American Diabetes Association, were evalu-
ated from November 2015 to July 2016. The exclusion 
criteria of the study were: vegetarianism, veganism, 
patients with non-absorptive diseases, chronic end-
stage renal disease or usage of cobalamin formulations 
in the previous 6 months.  
Data collection
All selected patients were interviewed by a single 
physician about how long they had been suffering from 
diabetes, type of diet, medications used in the previous 
6 months (detailed information about the use of met-
formin, anti-acids, supplements or any other medica-
tions). In detailing the use of metformin, we considered 
users those who had used that medicine for at least 
the previous 3 months. They were also questioned by 
the dosage of metformin. The Neuropathy Symptom 
Score (NSS) was used to detect neuropathic symptoms 
[18, 19]. We used the criteria adopted by the Diagnos-
tic and Statistical Manual of Mental Disorders of the 
American Psychiatric Association, 5th Edition (DSM-5) 
for the diagnosis of Alcohol Use Disorder.
The patients underwent a complete physical ex-
amination, including examination of both feet. To test 
the sensitivity to vibration, we used a 128-Hz tuning 
fork that was positioned on the dorsal side of the hal-
lux and classified the response as normal or decreased 
[18]. The achilles reflex test was classified as absent, 
diminished, or normal [18]. Sensitivity to mechanical 
pressure was tested using the 10-g Semmes-Weinstein 
monofilament, positioned at four different points on 
each foot: plantar regions of the hallux and first, third 
and fifth metatarsals. The detection of any insensitivity 
point was considered altered [20].
The clinical diagnosis of neuropathy was consid-
ered in case of any combination of two of the following 
findings: neuropathic symptoms, decreased sensitivity 
(vibration or mechanical pressure) or decreased reflexes 
of the Achilles tendon [21]. The diagnosis of possible 
neuropathy was considered in case either one of these 
findings were detected.
Laboratory evaluation
Blood samples were collected for measuring of 
glucose, glycated hemoglobin (HbA1c), creatinine, lipid 
profile, iron, ferritin, folic acid, aspartate transaminases, 
alanine transaminases, thyroid stimulating hormone, 
free thyroxine and complete blood count. We excluded 
end-stage renal failure by estimating the glomerular 
filtration rate using the proposed Modification of Diet in 
Renal Disease (MDRD) formula. The serum vitamin B12 
level was quantified by chemiluminescent assay in the 
same laboratory and it was repeated on the following 
day in order to increase the reproducibility of the test. In 
order to classify vitamin B12 levels, we considered two 
measurements. As a cut-off, we used values below the 
reference range (below 211 pg/mL), which were consid-
ered as B12 deficiency. That value (below 211 pg/mL) 
is the cut-off used in kits by Brazilian laboratories for 
vitamin B12 dosage, which use the chemiluminescence 
method; Equipment: Architect; Manufacturer: Abott.
Statistical analyses
Patients with vitamin B12 deficiency were com-
pared with those without such deficiency as to identify 
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possible risk factors, such as metformin use or use of 
other medications, duration of the T2DM, gender and 
age. In addition, within the metformin user group, a 
linear regression analysis was performed in order to 
correlate the metformin dose with vitamin B12 levels. 
Finally, vitamin B12 levels were compared between 
the two groups of patients, with negative and positive 
neuropathy screening.
The analyses of association between the variables 
were performed through comparison between groups, 
correlations and linear regressions. Comparisons be-
tween the quantitative variables were analyzed using 
the Student’s t test or the Mann-Whitney test, as ap-
propriate. Categorical variables were analyzed using the 
chi-square test. The analysis of the association between 
continuous variables was performed either by means 
of correlation tests (Pearson or Spearman, as appropri-
ate) or by simple and multiple linear regression tests 
to estimate the independent influence of the predictor 
variables in the outcomes. We used following analysis 
models: univaried, multivaried, linear regression and 
multiple regression. Regression models were built 
based on possible risk factors of the sample including 
the use of medicine. Simple regressions were carried 
out with all identified variables and, those that showed 
a correlation at the univaried analysis were reanalyzed 
through multivaried regression in order to have a pos-
sible independent effect assessed.
Sample size was calculated by Epi Info Software 
based on estimated prevalence of vitamin B12 defi-
ciency in our population, whose sampling power was 
estimated to be 80%.
All statistical analysis was performed with Sigma-
Stat for Windows (version 3.5, SPSS, Inc., San Rafael, 
CA). Values of p < 0.05 were considered statistically 
significant. 
Results
A total of 316 patients with T2DM were investi-
gated. From which, 91% were using metformin for 
an average period of time of  9.8 years. The general 
characteristics of the group, including the profile of the 
medications in use, are presented in Table 1. 
On average, the group had good metabolic control, 
with a mean HbA1c level of 7.3 ± 1.3%, mean HDL cho-
lesterol level of 46 ± 11 mg/dL, mean LDL cholesterol 
level of 86 ± 30 mg/dL, and mean triglyceride level of 
137 ± 70 mg/dL. 
Vitamin B12 deficiency was observed in 14% of 
patients with high reproducibility, as shown at Figure 1. 
Statistical analysis of the group showed that all 
individuals with vitamin B12 deficiency were using 
metformin. The risk of vitamin B12 deficiency was sig-
nificantly higher in those who used doses greater than 
1000 mg/day of metformin (odds ratio [OR] 2.6, 95% 
CI 1.3–5.3, p = 0.009) (Table 2). Furthermore, in the 
multiple linear regression models, there was a direct 
and independent linear association between vitamin 
B12 levels and metformin dose with statistical signifi-
cance (p = 0.001) (Table 3). Vitamin B12 deficiency was 
also associated with a significantly higher prevalence 
of sulfonylurea use, as well as the use of angiotensin-
converting enzyme inhibitors (ACEI). In contrast there 
was no association between vitamin B12 deficiency 
and time of metformin use (p = 0.102) or use of other 
medications (Table 2).
Multiple regression analyzes confirmed an inde-
pendent association between vitamin B12 deficiency 
and metformin use at doses higher than 1000 mg/day 
(p = 0.019) as well as with the use of ACEI (p = 0.02), 
and no correlation was found with other medications 
(Table 4).
We observed that the Neuropathy Symptom Score 
(NSS) was positive in 39% of all patients tested. There 
was no significant association between the vitamin B12 
deficiency and the detection of neuropathy by any of 
the methods used (Table 2).  
Table 1. General characteristics of the studied group
General data
Sex F : M* 237 (75) : 79 (25)
Age (years)** 63.8 (9.2)
Duration of T2DM diagnosis (years)*** 10 (5–15)
Body mass index [kg/m²]*** 30 (26–33)
Smoking* 20 (6%)
Alcohol use* 8 (3%)
Medications in use
Metformin* 286 (91)
Duration of metformin use (years)*** 9.8 (6.0–13.0)
Metformin dose [mg]*** 2000 (1500–2550)
Statin* 236 (75)
Insulin* 142 (45)
Angiotensin II receptor blockers* 121 (39)
Angiotensin-converting  
enzyme inhibitors*
120 (38)
Aspirin* 115 (37)
Sulfonylurea* 94 (30)
Proton pump inhibitor* 76 (24)
Calcium channel antagonist* 57 (18)
Calcium supplements* 18 (6)
Other oral anti hyperglycemic agents* 14 (4)
Histamin antagonist* 5 (2)
*n (/%); **mean (SD); ***median (interquartile range); F — female;  
M — male; T2DM — type 2 diabetes mellitus
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Discussion 
In this group of patients with long-term T2DM and 
good metabolic control, we observed a prevalence of 
14% of vitamin B12 deficiency exclusively among met-
formin users. Previous studies have shown a prevalence 
of vitamin B12 deficiency of 10–30% among users of 
metformin and 4–7% among non-metformin users 
[5–7, 9]. The high prevalence of patients using met-
Table 2. Comparison of studied groups with and without vitamin B12 deficiency 
With deficiency Without deficiency p
N 43 270
Age (years)* 64.2 (10.7) 63.7 (9.0) 0.720
Sex (F) 77% 75% 0.920
Duration of T2DM (years)** 10 (8–16) 10 (5–14) 0.170
HbA1c (%)** 6.8 (6.3–7.8) 7.1 (6.3–8.1) 0.340
Folic acid [ng/mL]** 11.4 (7.9–14.0) 10.5 (7.9–13.2) 0.650
Metformin use
Percentage of  metformin 100% 89% 0.040
Duration of use (years)** 10.8 (7.9–13.8) 9.3 (5.8–12.9) 0.102
Dose [mg]** 2550 (1700–2550) 2000 (1500–2550) 0.016
Use of doses > 1000 mg/day  37% 22% 0.009
Others medications in use
ACEI 56% 35% 0.016
Sulfonylurea 44% 27% 0.040
PPI 19% 24% 0.510
Calcium supplements 0 6% 0.168
Neuropathy
Clinically probable neuropathy 35% 42% 0.490
*Mean (standard deviation); **median (interquartile distance); F — female; T2DM — type 2 diabetes mellitus; HbA1c — glycated hemoglobin;  
ACEI — angiotensin-converting enzyme inhibitor; PPI — proton pump inhibitor
Figure 1. Distribution of B12 levels in the sample. Vitamin B12 levels × numbers of patients tested
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Table 3. Multiple linear regression models — metformin 
dose × vitamin B12 levels
Models Coefficient Standart  
error
t p
Constant 344.198 116.115 2.964 0.003
Metformin 
dose
–0.0485 0.0146 –3.31 0.001
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formin has come to our attention. This medication is the 
first choice drug for treating diabetes and it has been 
used in large scale. This might have limited the power 
of analysis on the impact of metformin consumption.
The association between metformin use and vita-
min B12 deficiency has recently been confirmed in two 
meta-analyzes [22, 23], one involving 8.089 patients, 
which demonstrated that treatment with metformin 
use is associated with average reduction of 66 pmol/L 
in vitamin B12 concentrations. This contributes to a 
2.4-fold higher risk of vitamin B12 deficiency among 
users of this medication [22].
In the present study, the relationship between the 
use of metformin and the occurrence of vitamin B12 
deficiency demonstrated a clear dose-dependence 
relationship but no association related to duration of 
metformin use was found. In our study, we concluded 
that doses higher than 1000 mg have shown independ-
ent association with the vitamin B12 deficiency.
In a case-control study [24], the most important risk 
factor for vitamin B12 deficiency was the use of high 
doses of metformin, which for each 1 gram increase 
in metformin dose contributed to a 2-fold increase in 
the risk of this vitamin deficiency. Although the dura-
tion of metformin use has also been indicated as a risk 
factor for vitamin B12 deficiency in some studies [7, 
24], such association was not observed in this analysis. 
One reason why we could not find any relationship 
between the duration of metformin  use and vitamin 
B12 deficiency might be related to the fact that patients 
had been using metformin for an average period of 4.6 
years, the time duration the liver might be running out 
of its reserve of this vitamin.
Among other medications in use, there was an 
independent association between the use of ACEI and 
vitamin B12 deficiency. This association has not been 
demonstrated by any other study published so far. 
This result demonstrated the difficulty of detecting an 
independent metabolic effect for metformin in samples 
from patients using a wide variety of medications. We 
could propose a possible mechanism that would trigger 
such occurrence as a factor that determines the altera-
tion of absorptive mechanisms of vitamin in patients 
using multiples drugs such as ACEI.
In our analysis, we found that 41% of patients had 
a clinically detectable peripheral neuropathy, which 
was established by any combination of two of the 
following findings: neuropathic symptoms, alteration 
in sensibility (vibratory or mechanical pressure) and 
alteration of achilles reflex, 29% of patients did not 
show any symptoms of clinical signs tested for neu-
ropathy and 30% showed only one criterion, which 
makes diagnosis of neuropathy questionable. Despite 
high incidence of neuropathy in our population, we 
found this complication to be significantly lower 
among metformin users.
Regarding clinical screening for peripheral neu-
ropathy, it is noteworthy that, similar to other studies 
[25–27], there was no significant association between 
vitamin B12 deficiency and clinical neuropathy. Al-
though there was a clear association between the 
use of metformin and the vitamin B12 deficiency, our 
findings did not demonstrate clinical impact in the 
main consequence of this deficiency. Several authors 
have been able to demonstrate a decrease in the serum 
concentrations of cobalamin among metformin users, 
but neither one of them could find clinical neuropathic 
consequences of this vitamin deficiency [9, 25, 28, 29].
Conclusions
In conclusion, this study reinforces the direct 
association between the use of increasing doses of 
metformin and the deficiency of vitamin B12, also 
suggesting an association between this micronutrient 
deficit with the use of ACEI. In contrast, our findings 
minimize the hypothesis that vitamin B12 deficiency is 
associated with a significant increase in the prevalence 
of clinically detectable neuropathy in individuals with 
T2DM. Further studies are needed to provide a better 
understanding of the effects of metformin on vitamin 
B12 metabolism, as well as to verify the clinical impor-
tance of these findings. This is important to predict and 
propose better low-cost screening tests for all patients 
withT2DM using metformin.
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